Anzeige
Mehr »
Dienstag, 15.09.2026 - Börsentäglich über 12.000 News
Kupfer bei 7 Dollar: Wer hat die nächste Mine?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2JL4Z | ISIN: US68401U2042 | Ticker-Symbol:
NASDAQ
14.09.26 | 21:59
7,770 US-Dollar
+6,58 % +0,480
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
OPTIMIZERX CORPORATION Chart 1 Jahr
5-Tage-Chart
OPTIMIZERX CORPORATION 5-Tage-Chart

Aktuelle News zur OPTIMIZERX Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
OPTIMIZERX Aktie jetzt für 0€ handeln
MoOptimizeRx Corporation: OptimizeRx Expands Natural Language Audience Builder to Unify HCP and DTC Audience Intelligence1
02.09.OptimizeRx Corporation: OptimizeRx Appoints Pharma Commercialization and AI Expert Troy Sarich as Company Advisor1
20.08.OptimizeRx Corp - S-8, Securities to be offered to employees in employee benefit plans1
14.08.Citizens raises OptimizeRx stock price target on macro stability1
13.08.OptimizeRx Corp - 10-Q, Quarterly Report3
13.08.Stifel cuts OptimizeRx stock price target on revenue headwinds1
13.08.OptimizeRx reiterates $95M-$100M 2026 revenue outlook amid CFO transition1
12.08.Earnings Call: OptimizeRx übertrifft Gewinnprognose für Q2 2026, Aktie gibt dennoch nach1
12.08.OptimizeRx names Andy D'Silva CFO1
12.08.OptimizeRx names Andy D'Silva as CFO, Heather Favazza as CAO2
12.08.OptimizeRx Corporation: OptimizeRx Announces Finance Leadership Appointments to Support the Next Phase of Growth181The Company Names Andy D'Silva as the next Chief Financial Officer and Heather Favazza as Chief Accounting Officer effective January 1, 2027 Planned Transition Reflects Strong Succession Planning...
► Artikel lesen
12.08.OptimizeRx Corp - 8-K, Current Report1
12.08.OptimizeRx Corporation: OptimizeRx Reports Second Quarter 2026 Financial Results and Updates Fiscal Year 2026 Guidance326- Q2 revenue totals $20.5 million- Q2 net loss and adjusted EBITDA of $(0.7) million and $4.9 million, respectively- Reaffirms fiscal year 2026 revenue guidance of $95 - $100 million and adjusted...
► Artikel lesen
23.07.OptimizeRx Corporation: OptimizeRx Appoints Veteran Point of Care Marketing Leader Sarah Bast as Chief Marketing Officer246WALTHAM, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage...
► Artikel lesen
30.06.OptimizeRx launches CopayCue for prescription savings2
30.06.OptimizeRx Corporation: OptimizeRx Launches CopayCue, a Next-Generation Copay Activation Solution Powered by Real-Time Prescribing Intent340WALTHAM, Mass., June 30, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage...
► Artikel lesen
29.06.Stifel reiterates Buy on OptimizeRX stock, cites AI tool launch2
29.06.Citizens bestätigt "Market Outperform" für OptimizeRx Aktie2
29.06.OptimizeRx stock rating maintained at Market Outperform by Citizens1
25.06.OptimizeRx Corporation: OptimizeRx Launches Natural Language Audience Builder for Life Sciences DSPs and Agency Media Planning Platforms1
Weiter >>
40 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1